Vivia’s anti-proliferative assay provides the best conditions for patient-derived B cells ex vivo culture, allowing a wide variety of therapeutic compounds screening.
Proliferative B cells are crucial in autoimmune diseases through autoantibody production, antigen presentation, cytokine secretion, and ectopic germinal center formation. Inhibiting their proliferation limits these effects and balances regulatory and autoreactive B cells, essential for immune homeostasis. Therapies that inhibit B cell activity, like anti-CD20 antibodies, JAK, and mTOR inhibitors improve the management of rheumatoid arthritis, lupus, and multiple sclerosis.
The combination of CpG (B-class ODN2006) plus human stromal cell line HS5 (doi: 10.18632/oncotarget.25419) prevents patient-derived spontaneous cell death, promotes the proliferation of B cells, and immunoglobulin secretion.
It makes our assay the ideal platform to evaluate B cell response to stimuli.
Vivia’s B cell ex vivo assays can help your new autoimmune diseases therapy development.
Our B cell Proliferative can be used to:
- Evaluate novel autoimmune therapies targeting both B-cell antiproliferation and immunoglobulin secretion
- Compare new drugs vs established standard of care autoimmune diseases therapy compounds
- Compare drugs toxicity in healthy vs autoimmune disease-derived patient samples